Deloitte Launches CognitiveSpark™ for Marketing Artificial Intelligence Solution

Deloitte Launches CognitiveSpark™ for Marketing Artificial Intelligence Solution

NEW YORK, Oct. 14, 2021 /PRNewswire/ — Deloitte today announced the launch of its ConvergeHEALTH CognitiveSpark™ for Marketing artificial intelligence (AI) precision engagement solution, a module of the CognitiveSpark suite. CognitiveSpark for Marketing harnesses the power of AI to boost digital marketing return on investment (ROI) for life sciences companies, helping marketers make AI-powered decisions at scale and with speed.

A recent Deloitte survey of biopharma executives found that digital innovation is now a burning priority, with 77% of those surveyed saying their organization considers “digital innovation as a competitive differentiator.” And in the same survey, 86% of commercial leaders pointed to “health care provider (HCP)/patient engagement as the top use case likely to be impacted by digital innovation.”

Digital transformation and ultimately how that transformation helps patients, is a key imperative for biopharma Clients. Clients want a solution that helps them identify new opportunities, personalize content to each customer’s journey, and create new insights and modeling to improve customer targeting and experiences. Most importantly, they want to better understand the latent drivers of customer behavior to deliver the information customers need to manage their health — all while preserving transparency and trust.

Life sciences companies face several challenges when using digital marketing approaches to improve patient engagement, including:

  • Siloed marketing and sales functions: “Stove pipe” patient marketing, and sales functions contribute to disconnected engagement.
  • Data access and integration challenges: Promotional data comes from a variety of sources, making it difficult to identify, integrate and leverage data from impression through to revenue increase.
  • Theoretical versus experiential business rules: Patient engagement strategies are often based on rigid and simple if/then business rules, making it difficult to identify and optimize engagement drivers.
  • Loosely coupled decisioning and engagement layers: Omni-channel patient engagement isn’t tied to a robust decisioning layer that can be fine-tuned to support marketing execution.

CognitiveSpark for Marketing addresses these challenges by providing a flexible approach to connect disparate data sets, breaking down traditional siloes for insight-driven decision-making. The modular, cloud-based product includes:

  • Integrated data sets: Combines brand impression data with patient longitudinal data to produce an integrated, de-identified data set for analysis.
  • Quality data sets: Integrates claim data from 320 million patient lives to provide a robust  foundation for analysis.
  • Leading AI technologies: Applies next-gen machine learning and analytic technologies to provide actionable insights and recommendations.
  • Multi-dimensional visualizations: Provides highly targeted and visual illustrations that translate the noise of data into consumable pieces of information.
  • Free form user analysis: Enables users to drill down into source data to generate their own queries and insights.

“Digital transformation enabled by AI and machine learning is affecting virtually every aspect of the life sciences value chain,” said Aditya Kudumala, principal, Deloitte Consulting LLP, in Deloitte’s life sciences technology practice. “And when deployed strategically, and scaled across the entire enterprise, AI can help life sciences companies reshape business models, streamline manufacturing, and enhance everything from research to clinical trials to product intelligence. That’s the vision for the CognitiveSpark Suite of products — use AI to bring big data to life and ultimately help life sciences companies be more personalized and authentic in how they engage with health care professionals, patients and other stakeholders.”

CognitiveSpark for Marketing features a focused set of marketing modules built off campaign, behavioral, and medical data — connected in a manner that is designed to provide data privacy, patient safety and security. The cloud-based solution can integrate within an existing marketing analytics ecosystem to generate knowledge and inform marketing spend across multiple channels.

“Patients are surrounded by advertisements for pharmaceutical and health care products, as well as multiple, confusing marketing messages; and at the same time brand teams inherently face a degree of uncertainty in every decision they make,” said Mark Miller, managing director with Deloitte Consulting LLP. “CognitiveSpark for Marketing brings precision and clarity to brand teams and the audiences they are trying to reach so there can be better engagement, more satisfying experiences and ultimately more trust with patients and partners.”

About the ConvergeHEALTH CognitiveSpark Suite
Deloitte develops AI offerings that span the life sciences value chain — from molecule to market — including products through its ConvergeHEALTH CognitiveSpark suite. These AI solutions can help biopharma automate data management for clinical trials; improve manufacturing yield and product quality; leverage patient-generated insights for product enhancement; and power precision patient engagement in marketing. The ConvergeHEALTH CognitiveSpark suite offers a robust, integrated suite of AI-driven capabilities, solutions and products. Built on Deloitte’s CortexAI™, a secure scalable multi-cloud infrastructure, the CognitiveSpark suite is also scalable and flexible enough to integrate with a client’s existing AI platforms. Using CognitiveSpark, life sciences companies can generate new transformative opportunities, drive operational efficiency, fuel business growth — and importantly, benefit patients.

For more information please visit:  https://www2.deloitte.com/us/CognitiveSpark-Marketing

About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly 90% of the Fortune 500® and more than 7,000 private companies. Our people come together for the greater good and work across the industry sectors that drive and shape today’s marketplace — delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthier society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Building on more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s more than 345,000 people worldwide connect for impact at www.deloitte.com.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

SOURCE Deloitte

Related Links

www.deloitte.com

Source link

No Comments

Post a Comment